NASDAQ:NERV - Minerva Neurosciences News Headlines

Sign in or create an account to add this stock to your watchlist.
$5.15 -0.26 (-4.81 %)
(As of 05/23/2019 04:00 PM ET)
Previous Close$5.41
Today's Range$5.11 - $5.40
52-Week Range$5.11 - $12.95
Volume187,500 shs
Average Volume137,859 shs
Market Capitalization$200.98 million
P/E RatioN/A
Dividend YieldN/A
Beta1.39

Headlines

Minerva Neurosciences (NASDAQ NERV) News Headlines

Source:
DateHeadline
Minerva Neurosciences Inc (NERV) Expected to Post Earnings of -$0.42 Per ShareMinerva Neurosciences Inc (NERV) Expected to Post Earnings of -$0.42 Per Share
www.americanbankingnews.com - May 17 at 8:48 AM
Minerva Neurosciences Inc (NERV) Major Shareholder Venture Associates L. Index III Sells 36,574 SharesMinerva Neurosciences Inc (NERV) Major Shareholder Venture Associates L. Index III Sells 36,574 Shares
www.americanbankingnews.com - May 16 at 8:38 PM
Venture Associates L. Index III Sells 134,828 Shares of Minerva Neurosciences Inc (NERV) StockVenture Associates L. Index III Sells 134,828 Shares of Minerva Neurosciences Inc (NERV) Stock
www.americanbankingnews.com - May 16 at 8:18 PM
Minerva Stock Drops On Initial Reaction To Data, But Multiple Catalysts Are On The WayMinerva Stock Drops On Initial Reaction To Data, But Multiple Catalysts Are On The Way
seekingalpha.com - May 14 at 8:00 PM
Minerva Neurosciences Inc.Minerva Neurosciences Inc.
www.barrons.com - May 13 at 7:55 PM
Minerva down 11% premarket on "successful" study of seltorexant in MDDMinerva down 11% premarket on "successful" study of seltorexant in MDD
seekingalpha.com - May 13 at 7:55 PM
Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression DrugMinerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug
finance.yahoo.com - May 13 at 7:55 PM
Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIsMinerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs
finance.yahoo.com - May 13 at 8:19 AM
Calculating The Fair Value Of Minerva Neurosciences, Inc. (NASDAQ:NERV)Calculating The Fair Value Of Minerva Neurosciences, Inc. (NASDAQ:NERV)
finance.yahoo.com - May 7 at 7:00 PM
Edited Transcript of NERV earnings conference call or presentation 6-May-19 12:30pm GMTEdited Transcript of NERV earnings conference call or presentation 6-May-19 12:30pm GMT
finance.yahoo.com - May 7 at 8:25 AM
Minerva Neurosciences (NERV) Posts  Earnings Results, Misses Estimates By $0.06 EPSMinerva Neurosciences (NERV) Posts Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - May 7 at 7:58 AM
Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2019 Results - Earnings Call TranscriptMinerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 7:40 PM
Minerva Neurosciences, Inc. (NERV) Q1 2019 Earnings Call TranscriptMinerva Neurosciences, Inc. (NERV) Q1 2019 Earnings Call Transcript
finance.yahoo.com - May 6 at 7:40 PM
Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business UpdatesMinerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates
www.globenewswire.com - May 6 at 8:22 AM
Minerva Neurosciences (NERV) Set to Announce Quarterly Earnings on MondayMinerva Neurosciences (NERV) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 2:50 PM
Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6,Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6,
www.nasdaq.com - April 29 at 6:42 PM
Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019
finance.yahoo.com - April 29 at 6:42 PM
A Look At The Competitors To Minervas RoluperidoneA Look At The Competitors To Minerva's Roluperidone
seekingalpha.com - April 17 at 8:19 AM
Minerva Neurosciences Presents Pre-Clinical Data Suggesting a Mechanistic Role of Roluperidone in Addressing Negative Symptoms of SchizophreniaMinerva Neurosciences Presents Pre-Clinical Data Suggesting a Mechanistic Role of Roluperidone in Addressing Negative Symptoms of Schizophrenia
finance.yahoo.com - April 11 at 9:14 AM
Minerva Neurosciences, Inc: Minerva Neurosciences to Host Webcast Event on SchizophreniaMinerva Neurosciences, Inc: Minerva Neurosciences to Host Webcast Event on Schizophrenia
www.finanznachrichten.de - March 18 at 8:01 PM
Minerva Neurosciences to Host Webcast Event on SchizophreniaMinerva Neurosciences to Host Webcast Event on Schizophrenia
www.nasdaq.com - March 18 at 8:01 PM
Minerva Neurosciences, Inc: Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business UpdatesMinerva Neurosciences, Inc: Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates
www.finanznachrichten.de - March 12 at 10:48 PM
Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q4 2018 Results - Earnings Call TranscriptMinerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 12 at 10:48 PM
Minerva Neurosciences Inc (NERV) Q4 2018 Earnings Conference Call TranscriptMinerva Neurosciences Inc (NERV) Q4 2018 Earnings Conference Call Transcript
finance.yahoo.com - March 12 at 10:48 PM
Edited Transcript of NERV earnings conference call or presentation 12-Mar-19 12:30pm GMTEdited Transcript of NERV earnings conference call or presentation 12-Mar-19 12:30pm GMT
finance.yahoo.com - March 12 at 10:48 PM
Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business UpdatesMinerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates
finance.yahoo.com - March 12 at 8:32 AM
Minerva Neurosciences: 4Q Earnings SnapshotMinerva Neurosciences: 4Q Earnings Snapshot
finance.yahoo.com - March 12 at 8:32 AM
Minerva Neurosciences to Report Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2019Minerva Neurosciences to Report Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2019
finance.yahoo.com - March 5 at 8:44 AM
How Much Of Minerva Neurosciences, Inc. (NASDAQ:NERV) Do Institutions Own?How Much Of Minerva Neurosciences, Inc. (NASDAQ:NERV) Do Institutions Own?
finance.yahoo.com - December 20 at 5:37 PM
Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on PainMinerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain
finance.yahoo.com - November 28 at 8:27 AM
Early-stage study shows potential expanded therapeutic window for Minervas roluperidoneEarly-stage study shows potential expanded therapeutic window for Minerva's roluperidone
seekingalpha.com - November 19 at 5:22 PM
Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy VolunteersMinerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers
finance.yahoo.com - November 19 at 8:19 AM
Minerva Neurosciences Sees Hammer Chart Pattern: Time to Buy?Minerva Neurosciences Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - November 16 at 8:16 AM
Minerva to host KOL event November 20Minerva to host KOL event November 20
seekingalpha.com - November 15 at 5:26 PM
Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018
finance.yahoo.com - November 15 at 5:26 PM
New Research: Key Drivers of Growth for AxoGen, Spirit Realty Capital, e.l.f. Beauty, Minerva Neurosciences, Par Pacific, and Calithera Biosciences — Factors of Influence, Major Initiatives and Sustained ProductionNew Research: Key Drivers of Growth for AxoGen, Spirit Realty Capital, e.l.f. Beauty, Minerva Neurosciences, Par Pacific, and Calithera Biosciences — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - November 9 at 8:23 AM
Minerva Delays Roluperidone Data, But Remains On Track For Transformational 2019Minerva Delays Roluperidone Data, But Remains On Track For Transformational 2019
seekingalpha.com - November 8 at 8:21 AM
Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 14, 2018Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 14, 2018
finance.yahoo.com - November 7 at 5:47 PM
Edited Transcript of NERV earnings conference call or presentation 5-Nov-18 1:30pm GMTEdited Transcript of NERV earnings conference call or presentation 5-Nov-18 1:30pm GMT
finance.yahoo.com - November 6 at 8:17 AM
Minerva Neurosciences reports Q3 resultsMinerva Neurosciences reports Q3 results
seekingalpha.com - November 5 at 5:23 PM
Minerva Neurosciences (NERV) CEO Remy Luthringer on Q3 2018 Results - Earnings Call TranscriptMinerva Neurosciences' (NERV) CEO Remy Luthringer on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 5 at 5:23 PM
BRIEF-Minerva Neurosciences Qtrly Loss Per Share $0.31BRIEF-Minerva Neurosciences Qtrly Loss Per Share $0.31
www.msn.com - November 5 at 8:34 AM
Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business UpdatesMinerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates
finance.yahoo.com - November 5 at 8:34 AM
Minerva Neurosciences: 3Q Earnings SnapshotMinerva Neurosciences: 3Q Earnings Snapshot
finance.yahoo.com - November 5 at 8:34 AM
Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018
finance.yahoo.com - October 29 at 5:02 PM
Analysis: Positioning to Benefit within Kopin, MDC Partners, Dova Pharmaceuticals, Revlon, ImprimisAnalysis: Positioning to Benefit within Kopin, MDC Partners, Dova Pharmaceuticals, Revlon, Imprimis
www.nasdaq.com - October 16 at 8:24 AM
Analysis: Positioning to Benefit within Kopin, MDC Partners, Dova Pharmaceuticals, Revlon, Imprimis Pharmaceuticals, and Minerva Neurosciences — Research Highlights Growth, Revenue, and Consolidated ResultsAnalysis: Positioning to Benefit within Kopin, MDC Partners, Dova Pharmaceuticals, Revlon, Imprimis Pharmaceuticals, and Minerva Neurosciences — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - October 16 at 8:24 AM
Minerva Neurosciences Inc (NASDAQ:NERV): Risks You Need To Consider Before BuyingMinerva Neurosciences Inc (NASDAQ:NERV): Risks You Need To Consider Before Buying
finance.yahoo.com - October 10 at 5:02 PM
The Verdict On MinervaThe Verdict On Minerva
seekingalpha.com - October 9 at 4:56 PM
A Look At Johnson & Johnsons Late Stage Pharmaceuticals PipelineA Look At Johnson & Johnson's Late Stage Pharmaceuticals Pipeline
www.forbes.com - September 26 at 5:07 PM
This page was last updated on 5/23/2019 by MarketBeat.com Staff

Featured Article: How Do Mutual Funds Work?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel